LICENSE AND SUPPLY AGREEMENT (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received	$ 60,000
Revenue recognized over designated period of relationship	4,600
Revenue recognition period	14 years
Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	40.00%
Collaboration Operation [Member]
Significant Accounting Policies [Line Items]
Accrued liabilities accrued related to the Collaboration Operation	8,500
Accrued long term liabilities	5,400
Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	60.00%
Upon Filing of Pediatric Investigation Plan to EMA [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received	5,000
Upon each FDA and European Medicine Agency approval [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	25,000
Upon FDAApproval [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	25,000
Upon Near Term Clinical Development Milestones [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	$ 8,300